Hasil Pencarian - Vivian Scheuplein

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    225 Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs

    225 Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs oleh Matthias Leisegang, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Ioannis Gavvovidis

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo

    In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo oleh Gerald Willimsky, Christin Beier, Lena Immisch, George Papafotiou, Vivian Scheuplein, Andrean Goede, Hermann-Georg Holzhütter, Thomas Blankenstein, Peter M Kloetzel

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    95 MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy

    95 MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy oleh Ronald Simon, Thomas Blankenstein, Jennifer Oduro, Natalia Gorbokon, Christoph Fraune, Julia Bluhm, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial)

    499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial) oleh Fiona Thistlethwaite, Sylvie Rottey, Emiliano Calvo, Antonia Busse, Martin Wermke, Ralf Wolter, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Eugen Leo, Ioannis Gavvovidis, Marie-Luise Goebeler, Nuria Kotecki, Carolina Perdomo-Ortiz

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors

    Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors oleh Lena Immisch, Lena Immisch, Lena Immisch, George Papafotiou, George Papafotiou, George Papafotiou, Nerea Gallarín Delgado, Vivian Scheuplein, Annette Paschen, Annette Paschen, Thomas Blankenstein, Thomas Blankenstein, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma

    A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma oleh Josefine Krüger, Matthias Obenaus, Igor Wolfgang Blau, Dana Hoser, Martin Vaegler, Hana Rauschenbach, Ioannis Anagnostopoulos, Korinna Jöhrens, Vivian Scheuplein, Elisa Kieback, Judith Böhme, Ann-Christin von Brünneck, Jan Krönke, Antonia Busse, Gerald Willimsky, Thomas Blankenstein, Antonio Pezzutto, Ulrich Keller, Axel Nogai

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: